Scopus Biopharma (SCPS) Stock Price, News & Analysis
Company Description
Scopus Biopharma (OTC Link: SCPS) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $12.6K.
SCPS has gained 66.7% over the past year. Shares last traded at $0.0005.
For FY2022, Scopus Biopharma reported revenue of $0 and diluted earnings per share of $-0.55.
This page collects what Stock Titan holds for SCPS, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Scopus Biopharma (SCPS) stock last closed at $0.0005. Over the past 12 months, the stock has gained 66.7%. At a market capitalization of $12.6K, SCPS is classified as a micro-cap stock with approximately 42.1M shares outstanding.
Latest News
Scopus Biopharma has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include conferences, management. View all SCPS news →
SEC Filings
Financial Highlights
Diluted earnings per share stood at $-0.55.
Upcoming Events
Short Interest History
Short interest in Scopus Biopharma (SCPS) currently stands at 10.5 thousand shares, representing 0.0% of the float. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Scopus Biopharma (SCPS) currently stands at 2.0 days, down 85.2% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has decreased 94.6% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 228.4 days.
SCPS Company Profile & Sector Positioning
Scopus Biopharma (SCPS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing SCPS often look at related companies in the same sector, including Virpax Pharmaceuticals Inc (VRPX), Q Biomed (QBIO), Biostax Corp (BTAX), Evelo Biosciences (EVLO), and Renovacare (RCAR). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SCPS's relative position within its industry.